Literature DB >> 7632929

Peripheral T-cell lymphoma in lckpr-bcl-2 transgenic mice.

G P Linette1, J L Hess, C L Sentman, S J Korsmeyer.   

Abstract

t(14;18) is the most common translocation in human lymphoid malignancy and results in bcl-2 overexpression. Bcl-2 blocks apoptosis and constitutes the initial member of a new category of oncogenes, ie, regulators of cell death. Bcl-2-Ig transgenic mice develop follicular hyperplasia and progress to malignant B-cell lymphoma. To assess the oncogenic potential of bcl-2 in the T-cell lineage, a cohort of 68 lckpr-bcl-2 transgenic mice and 56 control littermates were monitored for signs of malignancy over a 24-month period. Eighteen (26%) lckpr-bcl-2 mice developed diffuse, predominantly large-cell lymphomas at a mean age of 18 months. In contrast, only one nontransgenic control mouse developed lymphoma. CD3 surface expression and clonal T-cell receptor beta rearrangements support the T-lineage classification of these neoplasms. lckpr-bcl-2-enforced lymphomas are predominantly CD4+CD8-, consistent with a mature peripheral T-cell phenotype. These data provide support for the thesis that violation of homeostasis through the repression of cell death can be a primary mechanism of tumorigenesis in multiple lineages.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7632929

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

Review 1.  A portrait of the Bcl-2 protein family: life, death, and the whole picture.

Authors:  M Pellegrini; A Strasser
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

2.  Bcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway.

Authors:  Qinhong Wang; Fengqin Gao; W Stratford May; Yangde Zhang; Tammy Flagg; Xingming Deng
Journal:  Mol Cell       Date:  2008-02-29       Impact factor: 17.970

3.  The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry.

Authors:  D C Huang; L A O'Reilly; A Strasser; S Cory
Journal:  EMBO J       Date:  1997-08-01       Impact factor: 11.598

Review 4.  T Cells and Regulated Cell Death: Kill or Be Killed.

Authors:  Johan Spetz; Adam G Presser; Kristopher A Sarosiek
Journal:  Int Rev Cell Mol Biol       Date:  2018-08-29       Impact factor: 6.813

5.  The Gfi-1 protooncoprotein represses Bax expression and inhibits T-cell death.

Authors:  H L Grimes; C B Gilks; T O Chan; S Porter; P N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

6.  Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization.

Authors:  Qingqing Ding; Xianghuo He; Jung-Mao Hsu; Weiya Xia; Chun-Te Chen; Long-Yuan Li; Dung-Fang Lee; Jaw-Ching Liu; Qing Zhong; Xiaodong Wang; Mien-Chie Hung
Journal:  Mol Cell Biol       Date:  2007-03-26       Impact factor: 4.272

7.  BAC-mediated transgenic expression of fluorescent autophagic protein Beclin 1 reveals a role for Beclin 1 in lymphocyte development.

Authors:  I Arsov; X Li; G Matthews; J Coradin; B Hartmann; A K Simon; S C Sealfon; Z Yue
Journal:  Cell Death Differ       Date:  2008-05-02       Impact factor: 15.828

8.  G0 function of BCL2 and BCL-xL requires BAX, BAK, and p27 phosphorylation by Mirk, revealing a novel role of BAX and BAK in quiescence regulation.

Authors:  Yelena Janumyan; Qinghua Cui; Ling Yan; Courtney G Sansam; Mayda Valentin; Elizabeth Yang
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

9.  Histone Deacetylase 3 Is Required for Efficient T Cell Development.

Authors:  Kristy R Stengel; Yue Zhao; Nicholas J Klus; Jonathan F Kaiser; Laura E Gordy; Sebastian Joyce; Scott W Hiebert; Alyssa R Summers
Journal:  Mol Cell Biol       Date:  2015-08-31       Impact factor: 4.272

10.  Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase.

Authors:  Maohua Xie; Yun Yen; Taofeek K Owonikoko; Suresh S Ramalingam; Fadlo R Khuri; Walter J Curran; Paul W Doetsch; Xingming Deng
Journal:  Cancer Res       Date:  2013-11-06       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.